(Q24235483)

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Fabry disease: overall effects of agalsidase alfa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Clinical benefit in Fabry patients given enzyme replacement therapy--a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

High incidence of later-onset fabry disease revealed by newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Misleading funnel plot for detection of bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Publication bias in meta-analysis: its causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Clinical benefit of enzyme replacement therapy in Fabry disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006663.PUB2

7 January 2021